JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB265649

Human SERTAD3 knockout HeLa cell line

Be the first to review this product! Submit a review

|

(0 Publication)

SERTAD3 KO cell line available to order. KO validated by. Free of charge wild type control provided. Knockout achieved by using CRISPR/Cas9, 17 bp deletion in exon 2 and 1 bp insertion in exon 2.

View Alternative Names

AW124805, D1Mgi51, MGC108974, RPA-binding trans-activator, Rbt1, Replication protein-binding trans-activator, SERTA domain-containing protein 3, SERTAD3, SRTD3_HUMAN, Sei3

2 Images
Sanger Sequencing - Human SERTAD3 knockout HeLa cell line (AB265649)
  • Sanger seq

Unknown

Sanger Sequencing - Human SERTAD3 knockout HeLa cell line (AB265649)

Allele-2 : 1 bp insertion in exon 2.

Sanger Sequencing - Human SERTAD3 knockout HeLa cell line (AB265649)
  • Sanger seq

Unknown

Sanger Sequencing - Human SERTAD3 knockout HeLa cell line (AB265649)

Allele-1 : 17 bp deletion in exon 2.

Key facts

Cell type

HeLa

Species or organism

Human

Tissue

Cervix

Form

Liquid

form

Knockout validation

Sanger Sequencing

Mutation description

Knockout achieved by using CRISPR/Cas9, 17 bp deletion in exon 2 and 1 bp insertion in exon 2

Disease

Adenocarcinoma

Product details

Recommended control: Human wild-type HeLa cell line (ab255928). Please note a wild-type cell line is not automatically included with a knockout cell line order, if required please add recommended wild-type cell line at no additional cost using the code WILDTYPE-TMTK1.

We will provide viable cells that proliferate on revival.

This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our limited use license and patent pages.

What's included?

{ "values": { "1000000Cellsvial": { "sellingSize": "1000000 Cells/vial", "publicAssetCode":"ab265649-1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab265649 Human SERTAD3 knockout HeLa cell line", "number":"AB265649-CMP01" } ] }, "1000000Cellsvial": { "sellingSize": "1000000 Cells/vial", "publicAssetCode":"ab265649-1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab265649 Human SERTAD3 knockout HeLa cell line", "number":"AB265649-CMP01", "productcode":"" } ] } } }

Properties and storage information

Gene name
SERTAD3
Gene editing type
Knockout
Gene editing method
CRISPR technology
Knockout validation
Sanger Sequencing
Shipped at conditions
Dry Ice
Appropriate short-term storage conditions
-196°C
Appropriate long-term storage conditions
-196°C

Handling procedures

Initial handling guidelines

Upon arrival, the vial should be stored in liquid nitrogen vapor phase and not at -80°C. Storage at -80°C may result in loss of viability.

1. Thaw the vial in 37°C water bath for approximately 1-2 minutes.
2. Transfer the cell suspension (0.8 mL) to a 15 mL/50 mL conical sterile polypropylene centrifuge tube containing 8.4 mL pre-warmed culture medium, wash vial with an additional 0.8 mL culture medium (total volume 10 mL) to collect remaining cells, and centrifuge at 201 x g (rcf) for 5 minutes at room temperature. 10 mL represents minimum recommended dilution. 20 mL represents maximum recommended dilution.
3. Resuspend the cell pellet in 5 mL pre-warmed culture medium and count using a haemocytometer or alternative cell counting method seed all remaining cells into a T25.
4. Incubate the culture at 37°C incubator with 5% CO2. Check the culture one day after revival and continue to check until 80% confluent. Media change can be given if needed.
5. Once confluent passage into an appropriate flask at a density of 2x104 cells/cm2. Seeding density is given as a guide only and should be scaled to align with individual lab schedules. Cultures should be monitored daily.

Subculture guidelines
  • All seeding densities should be based on cell counts gained by established methods.
  • A guide seeding density of 2x104 cells/cm2 is recommended.
  • Cells should be passaged when they have achieved 80-90% confluence.
Culture medium

DMEM (High Glucose) + 10% FBS

Cryopreservation medium

Cell Freezing Medium-DMSO Serum free media, contains 8.7% DMSO in MEM supplemented with methyl cellulose.

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

The SERTAD3 protein also known as SEI1 or TRIP-Br1 acts mechanically by serving as a transcriptional regulator. It has a mass of approximately 33 kDa. SERTAD3 is expressed in various human tissues with increased levels in the heart brain and skeletal muscle. It engages in interactions with other transcription factors which modulate cell cycle progression and proliferation.
Biological function summary

SERTAD3 plays a role in cellular growth and division processes. As a part of multi-protein complexes it interacts with cyclin-dependent kinase 4 (CDK4) and cyclin D1. This interaction helps regulate the cell cycle particularly influencing the transition from the G1 to the S phase. SERTAD3 contributes significantly to controlling cell division making it important for maintaining normal cellular homeostasis.

Pathways

Several aspects of cell cycle regulation involve SERTAD3. It is an important participant in the cyclin D-CDK4/6 signaling pathway which is necessary for cell cycle progression. SERTAD3 interacts with retinoblastoma protein (pRB) through this pathway impacting its phosphorylation status and thereby influencing cell cycle control. The interaction helps facilitate proper DNA synthesis and replication.

SERTAD3 has connections to certain cancers and cardiovascular diseases. Overexpression of SERTAD3 has been observed in some cancers such as breast cancer which suggests its role in facilitating uncontrolled cellular proliferation. In this context it interacts closely with proteins like pRB affecting pathways that lead to tumorigenesis. Additionally its regulation of cell cycle processes implies potential involvement in heart diseases where abnormal cell cycle re-entry is a concern.

Quality control

STR analysis

CSF1PO, D13S317, D7S820, D5S818, TH01, D16S539, TPOX

Cell culture

Biosafety level

EU: 2 US: 2

Adherent/suspension

Adherent

Gender

Female

Product protocols

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com